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A unifying mechanism for abused drugs has been proposed 
previously from the standpoint of electron transfer. Mescaline 
can be accommodated within the theoretical framework based 
on redox cycling by the catechol metabolite with its quinone 
counterpart. Electron transfer may play a role in electrical effects 
involving the nervous system in the brain. This approach is in 
accord with structure activity relationships involving mescaline, 
abused drugs, catecholamines and etoposide. Inefficient demeth-
ylation is in keeping with the various drug properties, such as 
requirement for high dosage and slow acting.
There is a discussion of receptor binding, electrical effects, cell 
signaling and other modes of action. Mescaline is a nonselective, 
seretonin receptor agonist. 5-HTP receptors are involved in the 
stimulus properties. Research addresses the aspect of stereochem-
ical requirements. Receptor binding may involve the proposed 
quinone metabolite and/or the amino sidechain via protonation. 
Electroencephalographic studies were performed on the effects of 
mescaline on men. Spikes are elicited by stimulation of a cortical 
area.  The  potentials  likely  originate  in  nonsynaptic  dendritic 
membranes. Receptor-mediated signaling pathways were exam-
ined which affect mescaline behavior. The hallucinogen belongs 
to the class of 2AR agonists which regulate pathways in cortical 
neurons.  The  research  identifies  neural  and  signaling  mecha-
nisms  responsible  for  the  biological  effects.  Recently,  another 
hallucinogen, psilocybin, has been included within the unifying 
mechanistic framework. This mushroom constituent is hydro-
lyzed to the phenol psilocin, also active, which is subsequently 
oxidized to an ET o-quinone or iminoquinone.
Introduction
The use of mescaline (peyote) (1) (Scheme 1), a psychedelic 
drug present in various types of cactus, was reported in religious 
ceremonies of North American natives by early Europeans. For 
centuries, North American Indians used mescaline as a medicine, 
amulet and hallucinogenic religious sacrament.1 Primitive peoples 
associated the plant action with the supernatural. Vestiges of the 
cults that survived, flourished and expanded to a large intertribal 
religion  as  late  as  1973.  No  significant  harm  is  evident  from 
chronic consumption during these ceremonies, although adverse 
effects have been reported. It is claimed that the drug is neither 
habit-forming nor addicting. Abuse of the substance is less than 
might be expected. Among the reasons are bitter taste, nausea and 
low potency. Research on the substance started more than 100 
years ago, and has continued at a vigorous pace. The drug was 
ruled illegal in the US in 1970.
In  vivo  synthesis  of  mescaline  in  1950,  in  the  cactus  was 
proposed as shown in Scheme 1.2 In 1969,3,4 intermediate steps 
were  further  elaborated.  Starting  with  tyrosine  (2),  the  main 
intermediates are dopa (3) dopamine (4) and 3,4,5-trihydroxy-β-
phenyethylamine (5), leading to mescaline (1).
Synthesis of Mescaline
Over the years, several synthetic methods have appeared for 
making mescaline from readily available trimethoxybenzene com-
pounds. Soderquist et al.5 converted trimethoxybenzene ketal to 
mescaline in good yields (Scheme 2). Another synthesis involving 
a  chromium  complex  was  reported  by  Rose-Munch  et  al.6 
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There  are  also  several  earlier  references  to  the  synthesis  of   
mescaline.7-9
The preponderance of bioactive substances or their metabo-
lites incorporate ET functionalities, which, we believe, play an 
important  role  in  physiological  responses.  These  main  groups 
include quinones (or phenolic precursors), metal complexes (or 
complexors),  aromatic  nitro  compounds  (or  reduced  hydroxy-
lamine  and  nitroso  derivatives),  and  conjugated  imines  (or 
iminium  species).  The  quinone  category  is  the  main  focus 
herein.
A  brief  summary  of  the  fundamental  biochemistry  of  the 
quinone  ET  functionality  would  be  instructive  as  foundation 
for the ensuing sections. Quinones undergo redox cycling with 
the  corresponding  hydroquinone  or  catechol  with  intermediate 
involvement of semiquinones. In vivo redox cycling with oxygen 
can occur giving rise to oxidative stress (OS) through generation 
of reactive oxygen species (ROS). In some cases, ET results in 
interference with normal electrical effects, e.g., in respiration or 
neurochemistry. ET may be associated with bioelectrical events 
occurring in the brain in response to the action of psychic drugs. 
Generally,  active  entities  possessing  ET  groups  display  reduc-
tion potentials in the physiologically responsive range, i.e., more 
Mescaline mechanism
Scheme 1. Biosynthesis of mescaline. Steps include oxidation of (2) to (3), decarboxylation to (4), oxidation to (5) and methylation to (1).
positive  than  -0.5  V.  o-Quinones  possess  particularly  favorable 
reduction  potentials.  ET,  ROS  and  OS  have  been  increasingly 
implicated  in  the  mode  of  action  of  drugs  and  toxins,  e.g., 
anti-infective agents,10 anticancer drugs,11 carcinogens,12 repro-
ductive  toxins,13  nephrotoxins,14  hepatotoxins,15  cardiovascular 
toxins,16 nerve toxins,17 mitochondrial toxins,18 abused drugs,19 
ototoxins,20  immunotoxins,21  eye  toxins,22  pulmonary  toxins23 
and  various  other  categories,  including  human  illnesses.24 This 
review demonstrates that the ET-ROS-OS unifying theme, which 
has been successful for many other classes of toxins and abused 
drugs, can also be applied to mescaline.
There is substantial precedent for ET involvement of catechol 
and o-quinone as a redox couple (see above). In the mescaline case, 
the suggested partners involved are catechol (6) and o-quinone (7), 
together with a semiquinone. A unifying mode of action based 
on ET has been applied to the principal abused drugs as well as 
abused therapeutic drugs19 (see below). The term bioelectronome 
refers to ET processes which are not only widespread in living 
systems, but are likely the most important chemical transforma-
tions.25 It is important to recognize that in vivo mode of action 
is  usually  multifaceted  with  various  factors  involved,  some  of 
which are interactive. The present proposed mechanism is the first Mescaline mechanism
a minor metabolite of mescaline in humans. Friedhoff 
and Goldstein30 have reported 3,4,5-trimethoxypheny-
ethanol as a mescaline metabolite in rats. Charalampous 
et  al.28  feeding  14C  labeled  mescaline  orally  isolated 
N-acylated mescaline and the 3,4-dimethoxy-5-hydroxy 
N-acetyl  derivative  from  the  urine.  Interestingly,  the 
N-acetyl derivative at high level of dosage 300–750 mg 
did show a mild degree of drowsiness (Fig. 2).
In  an  in  vitro  study  using  14C-labelled  mesca-
line  and  rabbit  liver  enzyme  preparation,  Daly  et 
al.31  showed  that  mescaline  is  demethylated  to  the 
2-hydroxy-1,3-dimethoxyderivative  (12)  and  the 
3-hydroxy-1,2-dimethoxyderivative (13) (Fig. 3).
Metabolism (Demethylation and Oxidation)
In  most  cases,  the  products  isolated  result  from 
sidechain  oxidation,  predominantly  3,4,5-trimethoxy-
phenylacetic  acid,31-33  and  to  a  lesser  extent  the 
corresponding aldehyde precursor.34 Other metabolites 
in  this  category  include  the  hydroxyethyl  derivative30 
and 3,4,5-trimethoxybenzoic acid.35
Our  mechanistic  approach  requires  dealkylation 
of  the  ether  groups  to  phenols.  In  an  earlier  study, 
compounds isolated comprise 3,4-dimethoxy-5-hydroxy-
phenethylamine,  the  3,5-dimethoxy-4-hydroxy  isomer 
and  3,4-dihydroxy-5-methoxyphenylacetic  acid.31  Of 
most relevance is conversion to the catechol form which, 
according to the hypothetical approach, is precursor to 
an ET o-quinone. The rate of demethylation is slow,36 
as also pointed out in another section. Data suggest that 
mescaline may be converted into some other substance 
which is directly responsible for the effects on the central nervous 
system.37
Relation of Demethylation Rate to Drug Properties
The rate of demethylation of anisole derivatives was determined 
by relative activity studies, ranging from 0 to 200%.38 The result 
was a quite low figure of 13% for mescaline which can be related 
to various drug properties. Large amounts of the drug are excreted 
unchanged,39 in accord with inefficient metabolism. Some have 
proposed that all of the drug is excreted suggesting that the parent 
is  the  active  form. This  statement  is  not  valid  since  there  are   
appreciable  numbers  of  reports  on  metabolism. 
Also, the drug is 1,000–3,000 times less potent 
than LSD. The effective human dose is 300–500 
mgs, which is much larger than for other related 
one addressing events at the fundamental molecular level, which   
also fits into a unifying theme for abused drugs (Fig. 1).
Mescaline Metabolism
In vivo studies on the metabolism of mescaline have shown 
that a large part of the mescaline combines with liver protein26 
and varying amounts are excreted unchanged or as the oxidatively 
deaminated 3,4,5-trimethoxyphenyacetic acid.27,28 Harley-Mason 
et  al.  isolated  3,4-dihydroxy-5-methoxyphenylacetic  acid  from 
human  urine  after  the  ingestion  of  mescaline,27  Ratcliffe  and 
Smith29 have found 3,4-dimethoxy-5-hydroxyphenyethylamine as 
Figure 1. Catechol and o-quinone metabolites of mesca-
line. The catechol-type metabolite (6) is part of a class 
that  readily  undergoes  redox  cycling  with  generation 
of an o-quinone product (7). The process is an oxida-
tive  transformation.  In  addition,  the  catechol  group 
readily complexes with heavy metals. Generally, such 
complexes are known to undergo electron transfer reac-
tions which, in the brain, may be involved in some of the 
physiological effects elicited by mescaline.
Scheme 2. Synthetic routes to mescaline. Various routes have been reported for labo-
ratory synthesis of mescaline. Key starting materials incorporate acetal, nitro alkene 
and chromium complex.
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incorporate  the  o-dimethoxy  precursor  of  the  subsequent  cate-
chol. Apparently, other factors are essential, such as metabolism 
and  receptor  binding.  Other  SAR  studies  involved  sidechain 
homologs,  such  as  3,4,5-trimethoxyphenylisopropylamine 
(3,4,5-trimethoxyamphetamine) (14).41 It is about twice as potent 
as mescaline (Fig. 4).
Extensive  structure-activity  relationship  studies,  carried  out 
over  several  decades  in  various  laboratories42-45  including  that 
of  Nichols,  have  led  to  a  good  general  understanding  of  the 
structural and stereochemical features that lead to hallucinogenic 
activity in substituted phenyethylamine derivatives, leading ulti-
mately  to  extremely  potent  substituted  amphetamines  such  as 
2,5-dimethoxy-4-bromoamphetamine (15) and 2,5-dimethoxy-4-
iodoamphetamine (15).
agents.  The  time  needed  for  maximum 
effect  may  be  up  to  2  hours,  which  is 
longer than for other drugs in the psychic 
class.33  It  is  important  to  recognize  that 
only small amounts are needed for notice-
able effect since the quinone ET action is 
catalytic, as is the case for many physiolog-
ically-active materials.
Structure-Activity Relationship of 
Phenylethylamine Hallucinogens
Mescaline is orally active, but it is the 
least potent of all the classical hallucino-
gens.  Despite  its  low  potency,  mescaline 
has  served  as  a  prototype  hallucinogen 
because  of  the  similarity  of  its  psychopharmacolgy  to  other   
hallucinogens and also because it is extensively used up to the 
present day in the form of peyote during religious services of the 
Native American Church. It also has served as the lead molecule in 
structure-activity relationship studies of the phenethylamines.
Mescaline.  A  quite  thorough  investigation  was  carried  out 
more than 40 years ago on SAR.40 The monosubstituted methoxy 
counterparts  are  inactive.  Also  inactive  are  all  disubstituted 
methoxy isomers. All trisubstituted compounds are inactive, except 
mescaline itself. The 2,3,4,5-tetramethoxy derivative is somewhat 
more  active  than  mescaline.  The  pentamethoxy  analog  is  the   
most  active,  indicating  that  sidechain  cyclization  to  the  indole 
derivative  may  not  be  important  for  mescaline.  In  relation  to 
the o-quinone approach, it is evident that all active compounds 
Figure 3. In vitro metabolic intermediates of mescaline. The process entails monodemethylation to 
phenolic diethers.
Figure 2. In vivo metabolism products of mescaline. These include demethylation and side chain modification.Mescaline mechanism
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with a number of these via catechol and o-quinone metabolites.   
The ones falling in this category are phenytoin, phenobarbital and 
aspirin.
Mescaline  and  catecholamines.  Catecholamines  comprise  an 
important class whose most prominent members are dopamine, 
epinephrine  (adrenaline),  norepinephrine  (noradrenaline)  and 
3,4-dihydroxyphenylalanine (DOPA). The substances are involved 
in neurotransmission and neurotoxicity.47 Much of their biochem-
istry stems from the catechol moiety which undergoes oxidation 
to  o-quinone  and  semiquinone.  Thus,  the  catechol  undergoes 
redox cycling with its quinone counterpart. Reported conversion 
of mescaline to catechols (see Metabolism section) lends credence 
to participation of ET as in the case of the catecholamine analogs. 
There is also similarity in the presence of an aminoethyl sidechain 
which is substituted in some cases.
Mescaline and etoposide. This drug, a 2,6-dimethoxyphenol 
derivative, is a semisynthetic analog of the antitumor antibiotic 
podophyllotoxin.11 Etoposide is metabolically activated by oxida-
tion and demethylation to an o-quinone derivative. The presence 
of molecular oxygen contributes to cytotoxicity, and DNA cleavage 
is  inhibited  by  radical  scavengers.  Also,  the  model  3-methoxy-
1,2-quinone exhibits a comparatively positive reduction potential 
(-0.16 V), making for facile electron uptake. This compound can 
also serve as a close model for both the etoposide metabolite and 
the proposed metabolite of mescaline. Metals, such as Fe or Cu, 
may play a role in ET via complex formation with the intermediate 
catechol.
Recently, psilocybin (16) has been added to drugs of the abused 
class19 which operate by ET mode of action.48 The substance, 
present  in  certain  mushrooms,  is  a  hallucinogen  belonging  to 
the  tryptamine  family.  It  has  been  banned  in  most  countries. 
In  vivo,  (16)  is  converted  by  dephosphorylation  into  a  phenol 
Interesting results are reported for compounds of structure(14)
in  which  nuclear  substitution  is  quite  different  from  that  of   
mescaline (1) (Fig. 5).46
Agents of general structure(14) are among some of the most 
potent hallucinogens known. These compounds have low nano-
molar affinities for serotonin 5-HT2A and 5-HT2c receptors, the 
primary sites believed to be involved in mediation of the unique 
behavioral effects of hallucinogens. Although the 1,2-dimethoxy 
grouping,  essential  for  catechol  type  formation,  is  missing,  the 
present  authors  believe  that  substances  of  type  (14)  can  be 
accommodated  within  the  general  mechanistic  framework. The 
1,4-dimethoxy  arrangement  in  (14)  can  serve  as  precursor  of  a 
hydroquinone  structure  via  demethylation,  which  might  then 
undergo  redox  cycling  with  the  corresponding  p-benzoquinone, 
analogous to the mechanistic proposal for mescaline.
Studies were made on the activity of the aldehyde and carboxylic 
acid metabolites of mescaline (see Metabolism).34 Pharmacological 
experiments on mice indicate that the metabolites are much less 
active or inactive in cataleptogenic effect and phenobarbital-induced 
sleep prolongation as compared with the parent compound. The 
reason is most likely the absence of the aminoethyl sidechain which 
may be important for binding. Other SAR data are available in the 
sections on abused drugs and catecholamines.
Mescaline  and  abused  drugs.  A  recent  review  provides  a 
unifying mechanism for toxicity and addiction by abused drugs 
based on ET-ROS.19 Evidence indicates that mescaline can also be 
incorporated within the broad framework. The drugs involved are 
nicotine, alcohol, phencyclidine, cocaine, methylenedioxymetham-
phetamine (MDMA, ecstasy), amphetamine, methamphetamine, 
morphine, heroin, delta-9-tetrahydrocannabinol, and lysergic acid 
diethylamide. Usually, metabolites are the active forms involved 
in  ET  and  OS.  Structural  analogy  can  be  drawn  involving 
mescaline  and  several  of  these,  based  on  catechol  and 
o-quinone as the active entities, namely MDMA, amphetamine, 
methamphetamine,  morphine  and  heroin.  In  the  amphetamine 
series, the 3,4,5-compound was twice as active as mescaline; the 
2,4,5-isomer was very active, and the 2,3,5-isomer was inactive.40
Various  therapeutic  drugs  fall  in  the  abused  category,  e.g., 
benzodiazepines, phenytoin, phenobarbital, aspirin and acetamino-
phen.19  Similarly,  mescaline  can  be  mechanistically  associated 
Figure 4. Sidechain homolog of mescaline. The data show that homologa-
tion of the sidechain to the isopropyl structure enhances the potency. This 
side chain is also present in Figure 5.
Figure 5. 2,5-Dimethoxyphenyl analog of mescaline. This analog on dem-
ethylation would yield a hydroquinone which could undergo redox cycling 
with its p-quinone partner.Mescaline mechanism
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Pharmocokinetics
Animals  show  slow  tolerance  to  repeated  administration. 
Intoxication can be alleviated or stopped with chlorpromazine or 
valium.
Psychic Effects
Individuals  experience  various  distortions,  involving  sensory 
perception,  space,  time,  color,  sounds  and  shapes,  as  well  as 
dreamlike feeling.46,56,57 There have been very few clinical studies 
employing mescaline, although it has a long history of use among 
the Native American population. Mescaline was studied to deter-
mine whether its effects were similar to the symptoms of acute 
psychosis. Hermie et al.57 showed, in normal male volunteers, that 
mescaline produced an acute “psychotic state” 3.5–4 h after drug 
administration as measured by the Brief Psychiatric Rating Scale 
(BPRS) and Paranoid Depression Scale (PDS).
(17)  (psilocin)  which  also  exhibits  psychedelic 
(hallucinogenic)  properties.  Studies  have  been 
carried out entailing enzymatic oxidation which 
provides  important  evidence  concerning  the 
mechanistic mode. The product from psilocin, 
possessing  a  deep  blue  color,  is  believed  to 
contain an o-quinone structure (18).49 A similar 
result  was  obtained  in  a  subsequent  investiga-
tion in which the product was assigned either 
an  o-quinone  (18)  or  iminoquinone  structure 
(19).50  Psilocybin  yielded  a  similar  result  in 
accord with facile hydrolysis to (17). o-Quinones 
display quite favorable ET properties. The data 
fit  nicely  into  the  prior  unifying  framework 
involving  participation  of  ET  entities  in  the 
physiological  activity.19  There  has  been  scant 
attention  to  action  mode  at  the  fundamental 
molecular level.
Pharmacological  studies  were  reported  on 
receptor  participation.51  Psilocin  behaves  as  a 
partial agonist at the 5-HT2A serotonin receptor 
in the brain. It is not surprising that the effects 
are somewhat related to those of serotonin which 
possesses a closely related structure (Fig. 6).
Physiological Effects
Mescaline  is  about  1,000–3,000  times  less 
potent than LSD (20) and about 30 times less 
potent  than  psilocybin  (16).43,52,53  Despite  its 
low  potency,  mescaline  has  served  as  proto-
type  hallucinogen  because  of  the  similarity  of 
its psychopharmacology to other hallucinogens. 
Death in animals results from convulsions and 
respiratory arrest. An effective dose of the sulfate, 
200–400  mg,  causes  hallucination  lasting  for 
about  10–12  h,54  compared  with  DMT  (21)   
(<1  h)  or  psilocybin  (4–6  h).  Brain  imaging 
showed mescaline selectively increases neuronal 
activity, especially in the striatolimbic systems in the right hemi-
sphere. Pàlenicek et al.55 showed mescaline had a delayed onset of 
the main behavioral changes in rats compared to other hallucino-
gens. Subcutaneous injection of mescaline leads to rapid increase in 
blood serum levels in 30 min and subsequently quickly decreased. 
Mescaline entered the brain slowly, and showed peak levels at 60 
min and remained high for an additional 60 min. Reaction to 
mescaline mimics the symptoms produced by norepinephrine and 
epinephrine, namely increase in heart rate, increase in tempera-
ture, nausea, dizziness, heavy perspiration, dilation of pupils, dry 
mouth and anxiety. In addition, coordination and reflux disrup-
tion, muscle weakness, increased blood pressure (hypertension), 
contraction of the intestines and the uterus are experienced by 
individuals after exposure to mescaline.56 Hermie et al.57 showed 
subjects  given  500  mg  of  mescaline  sulfate  produced  “hyper-
frontal” pattern of increased blood flow, which was correlated with 
mescaline-induced psychological effects (Fig. 7).
Figure 6. Metabolism of psilocybin to o- and imino-quinones. The process entails dephospho-
rylation to the phenol followed by oxidation to quinone-type products.Mescaline mechanism
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cis-  and  trans-2-(2,4,5-trimethoxyphenyl)-cyclo-
propylamine.61  The  trans  isomer  is  qualitatively 
indistinguishable from mescaline in relation to behav-
ioral effects. Potency is somewhat greater, and duration 
of action is briefer. In contrast, the cis isomer is almost 
inactive.  Calculations  on  the  docked  conformation 
indicate that this form is higher in energy than that 
in which the side chain is in the anti conformation. 
Insight was gained from investigations on C-(4,5,6-
trimethoxyindan-1-yl)methanamine, in which the side 
chain is considerably constrained by covalent linkage 
to the benzene ring.62 The compound possessed three-
fold  higher  affinity  and  potency  than  mescaline,  as 
well as equal efficacy at the 5-HT2A receptor. In drug 
discrimination studies, the indan derivative was five-
fold  more  potent.  Resolution  into  the  enantiomers 
showed the R-(+) isomer to be the active form. These 
studies of the effects of sidechain alteration are also 
relevant to the SAR section.
The quinone metabolite may be difficult to isolate 
since this class is known to bind readily to protein via 
conjugate addition by thiol or amino nucleophiles. 
Subsequent  oxidation  can  regenerate  the  quinone 
which would then redox cycle at the active site. This view is in 
keeping with the observation that large amounts of the drug are 
bound to protein.31 The side chain amino group of mescaline may 
also be involved in receptor binding via protonation by protein 
carboxyl.
Receptor chemistry in relation to ET-ROS and electrostatics 
is provided elsewhere (see sections on Electrical Effects and Cell 
Signaling).
Electrical Effects
A review was recently published on the importance of elec-
trical effects in living systems.63 Electroencephalographic (EEG) 
studies  were  performed  on  the  effects  of  mescaline  on  man.64 
  All-or-nothing spikes are elicited by antidromic, afferent or elec-
trical stimulation of a cortical area treated with the drug.65 The 
potentials  likely  originate  in  nonsynaptic  dendritic  membranes. 
A  depressant  cortical  reaction  induced  by  afferent  stimulation 
is influenced by the dendritic action potential from application 
of  mescaline.  An  EEG  arousal  is  brought  about  in  the  rabbit 
by  administration  of  the  drug.66  Evidence  indicates  that  some 
biochemical and neural patterns are common to both mescaline 
and morphine.67,68 Another section of this review addresses similar 
ET mechanisms for both cases, in line with the experimental obser-
vation. Results indicate an association between mescaline-induced 
pathological  aggression  and  abnormal  electrical  activity  in  the 
amygdale.69 A possible mechanism is discussed in rat studies, in 
which the drug inhibited the spontaneous firing of noradrenergic 
neurons  of  the  locus  ceruleus.70 There  was  increased  reactivity 
of these neurons to the excitory influences of peripheral stimuli. 
Results  suggest  that  nanosecond-pulsed  electric  fields  modulate 
cell signaling from the plasma membrane to intracellular structures 
and function.71 This technology could provide a powerful, unique 
Receptor Binding
Serotonin receptors are made up of G protein-coupled types 
and ligand-gated ion channels present in the CNS, which mediate 
neurotransmission via the release of neurotransmitters, in addition 
to hormones. These receptors play an important role in a variety 
of  processes,  such  as  anxiety,  cognition,  aggression,  learning, 
memory, nausea, sleep and mood. As a result, they are the target of 
therapeutic agents, as well as illicit drugs, including hallucinogens. 
There is a detailed discussion of hallucinogens and receptors in a 
2004 review.46
Mescaline  is  a  nonselective,  serotonin  receptor  agonist.55 
Data suggest that 5-HT2 receptors are involved in the stimulus 
properties  of  the  drug.58,59  Another  article  deals  with  receptor 
interaction  in  the  rat  striatum.60  Some  research  addresses  the   
aspect  of  stereochemical  requirements.  One  study  involved 
Table 1  Other mescaline mechanisms
    References
1  Alteration of normal metabolism in  81 
  such a way as to cause hallucinations.
2  A mescaline-protein complex is responsible for the  81 
  characteristic central effects.a
3  Competition of mescaline for adrenergic receptors.  81
4  Relationships between catecholamine  81 
  metabolites and mescaline.b
5  Cyclization to an indole.  81
6  In the periphery, mescaline blocks the release  82 
  of acetylcholine in muscle
aThis proposal is similar to the one in an earlier section dealing with receptor binding by the quinone 
metabolite. bWhich is related to a prior section.
Figure 7. Hallucinogens. These psychic drugs are used in comparison studies involving 
physiological activity.Mescaline mechanism
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The neuropsychological and neurometabolic effects of the drug 
were investigated with human subjects.84 Specific effects in the 
visual  systems  resulted.  A  hyperfrontal  pattern  in  the  face  was 
induced with emphasis on the right hemisphere; which was corre-
lated with induced psychotomimetic psychopathology. Mescaline 
operates selectively in the brain, stimulating regions to increased 
neuronal sctivity.85 Face-test studies were performed under mesca-
line-induced  psychosis.  Apparently,  the  potentiating  effect  of 
the drug is triggered by preferential actions on the serotogenic 
muscles.86,87 The behavioral effects were investigated for mesca-
line via intracerebroventricular administration.88 Rats exposed to 
mescaline exhibited enhanced spontaneous motility with no effect 
on  exploratory  behavior.89  The  influence  on  behavior  may  be 
related to change in the brain cholinergic system.
Hypotheses Testing
Experiments can be designed to test validity of the proposed 
action mechanism. The hypothesized catechol metabolite should 
be  synthesized  and  evaluated  for  activity.  Oxidation  yields  the 
o-quinone whose activity and reduction potential could be deter-
mined. In the enzyme system used for demethylation, addition 
of o-phenylenediamine can serve to trap the proposed o-quinone 
derivative, with formation of a readily identified product. Similarly, 
heavy metal ions can act to form complexes with the proposed 
catechol derivative.
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whose long-term effects are unknown.
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